Showing results (11-20 of 117) with videos related to
Sort By:
Pageof 12
Frontiers in Aging Neuroscience|May 7, 2020
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's DiseaseMicol Avenali, Fabio Blandini, Silvia CerriJournal of Parkinson'S Disease|July 9, 2019
Parkinson's Disease in Women and Men: What's the Difference?Silvia Cerri, Liudmila Mus, Fabio BlandiniNeural Regeneration Research|August 30, 2020
Potential therapeutic effects of polyphenols in Parkinson's disease: in vivo and in vitro pre-clinical studiesClaudio Giuliano, Silvia Cerri, Fabio BlandiniJournal of Neural Transmission (Vienna, Austria : 1996)|January 2, 2014
A further update on the role of excitotoxicity in the pathogenesis of Parkinson's diseaseGiulia Ambrosi, Silvia Cerri, Fabio BlandiniHandbook of Clinical Neurology|January 17, 2022
Noninvasive neuromodulation in Parkinson's disease: Neuroplasticity implication and therapeutic perspectivesGiuseppe Cosentino, Massimiliano Todisco, Fabio BlandiniExpert Opinion on Investigational Drugs|May 25, 2017
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesiasSilvia Cerri, Francesca Siani, Fabio BlandiniParkinsonism & Related Disorders|July 4, 2008
The 6-hydroxydopamine model: news from the pastFabio Blandini, Marie-Therese Armentero, Emilia MartignoniNeuroscience|December 26, 2022
Relevance of Biochemical Deep Phenotyping for a Personalised Approach to Parkinson's DiseaseClaudio Giuliano, Silvia Cerri, Valentina Cesaroni, et al.CNS & Neurological Disorders Drug Targets|August 9, 2021
Are Lysosomes Potential Therapeutic Targets for Parkinson's Disease?Alessandro Petese, Valentina Cesaroni, Silvia Cerri, et al.Frontiers in Neurology|April 4, 2019
Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?Marie Therese Fuzzati-Armentero, Silvia Cerri, Fabio BlandiniPageof 12